Drug Topics
APRIL 4, 2025
Researchers explored how entrustable professional activities can revolutionize workplace-based training and evolve the role of pharmacists within dermatology clinics.
STAT
APRIL 4, 2025
After Hurricane Ian, as Floridians returned home to sodden furniture and moldy piles of debris, many with asthma could feel their chests tightening. To figure out what was safe, some sent their concerns directly to the U.S. Centers for Disease Control and Prevention. But on Tuesday — days before floods ravaged Nashville, potentially prompting similar queries — the people who would normally answer such asthma questions stopped working.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 4, 2025
Researchers conducted a study to understand how community pharmacist referrals translated to the acceptance and completion of annual wellness visits.
STAT
APRIL 4, 2025
In a rare move, the Food and Drug Administration told an unspecified number of drug companies that studies used to support therapeutic equivalence of some of their medicines have been rejected due to false data generated by a contract research organization. The agency identified “significant” problems with data integrity and the way studies were conducted by Raptim Research, which had been hired by the drugmakers to test their medicines.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 4, 2025
Pharmacists can also provide education across all pillars of health, including exercise, wellness, and dietary changes.
STAT
APRIL 4, 2025
Food has been front and center in the Make America Healthy Again movement, Health Secretary Robert F. Kennedy Jr.’s campaign to solve chronic disease in the United States. That’s why forthcoming federal guidance on nutrition could draw extra attention this time around, even as a massive reorganization of the nation’s health workforce unfolds.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 4, 2025
There’s a theory of cancer causation that I’ve been thinking about recently called the two-hit hypothesis. It proposes that cancer begins with two mutations: one that can be inherited and one that is influenced by environmental or other factors. Public health seems to be in the midst of experiencing two hits. The result could be deadly.
Drug Topics
APRIL 4, 2025
Jenny Markell, BA, discussed the ongoing trends in prescription drug advertising and touched on her research into the impact it has on consumers.
STAT
APRIL 4, 2025
As a longtime dog owner, I assumed that each bag of my dogs’ commercial pet food was closely monitored by the federal Food and Drug Administration (FDA). It turns out I was wrong. More than 102 million U.S. households own a dog or a cat, and thousands more have fish, birds, or reptiles. The resulting pet food industry is massive — Americans spent $65 billion on pet food and treats in 2023 alone.
Drug Topics
APRIL 4, 2025
As pharmacists adapt to patient needs, pharmacists' mental wellness remains critical.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 4, 2025
Hello. Today, we dive into the implications of the ongoing cuts to various health and science agencies… It’s a doozy. Oh, and if you like talking about neuroscience and happen to be near San Diego this weekend, come hang with me and my colleagues at STAT@AAN : The Future of Brain Health.
Drug Topics
APRIL 4, 2025
Patients treated with the therapy showed significantly less progression of structural damage compared to patients who received placebo at week 24.
STAT
APRIL 4, 2025
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Drug Topics
APRIL 4, 2025
Pharmacists are transforming health care delivery by breaking down traditional barriers to medication access and patient care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
APRIL 4, 2025
New findings from The Pistoia Alliance report major challenges to adoption of data-driven innovation and AI in life sciences. The research is based on a poll conducted at the organisations annual European conference. Resistance to change emerged as the biggest obstacle to innovation (51 percent). To overcome this, the Alliance urged the pharmaceutical industry to prioritise cultural and behavioural change in digital transformation efforts.
PharmaVoice
APRIL 4, 2025
Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.
STAT
APRIL 4, 2025
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to promenade with the official mascots, catch up on our reading and look in on the Pharmalot ancestor. We also hope to hold yet another listening party, where the rotation will likely include this , this , this , this and this.
The Checkup by Singlecare
APRIL 4, 2025
Venlafaxine , commonly known by the brand name Effexor or Effexor XR, is a prescription drug used to manage symptoms of depression and other mood disorders. After being prescribed venlafaxine, you might wonder about your lifestyle choices while on this drug. A common question arises when people get invited to a social gathering or celebrationcan you enjoy a drink while taking venlafaxine?
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmafile
APRIL 4, 2025
A new progesterone-based treatment aimed at preventing miscarriage has been launched across the UK, following a major clinical trial that demonstrated a significant improvement in live birth rates. Prometrium, a 400mg soft vaginal capsule developed by Besins Healthcare, is now available in England, Wales, Scotland and Northern Ireland. It is designed for use by women […] The post New hormonal treatment launched to help prevent miscarriage in early pregnancy appeared first on Pharmafile.
Pharma Marketing Network
APRIL 4, 2025
In the world of pharma marketing, the strategies that truly resonate are often those rooted in trust. Thats why referral marketing is gaining traction among pharmaceutical brands looking to increase engagement with both healthcare professionals and patients. Rather than relying solely on paid ads or direct promotion, referral marketing uses personal recommendations to generate awareness, interest, and ultimately, conversions.
European Pharmaceutical Review
APRIL 4, 2025
Analytical testing is an essential part of guaranteeing the quality, safety and effectiveness of pharmaceutical products. However, the process is not without its challenges and it requires a proactive approach if both compliance and efficiency are to be maintained. This is why it is essential to develop and validate analytical methods to support activities and functions such as process validation controls, stability tests and dissolution profiles.
The Checkup by Singlecare
APRIL 4, 2025
Bonjesta is a brand-name prescription drug used to treat nausea and vomiting associated with pregnancy. This medication is an oral tablet that contains the medicines doxylamine and pyridoxine (a form of vitamin B6 ). Currently, there is not a generic version of Bonjesta. Managing nausea and vomiting during pregnancy is usually first controlled with diet and lifestyle adjustments.
Pharmafile
APRIL 4, 2025
Mehilinen, a Finnish health and social care provider, has announced that it has agreed to acquire Regina Maria and MediGroup. In conjunction with these, Hellman & Friedman (H&F) joins CVC in an investment partnership in the company. These developments form part of Mehilinens international growth strategy which focuses on expanding both in Finland and in […] The post Mehilinen acquires Regina Maria and MediGroup, and welcomes Hellman & Friedman as new shareholder appeared first
The Checkup by Singlecare
APRIL 4, 2025
Abilify (aripiprazole ) is a second-generation antipsychotic medicine used primarily in the treatment of bipolar disorder , schizophrenia , and depression. S econd-generation antipsychotics possess mood-stabilizing potential to go along with a lower risk of side effects than first-generation antipsychotics and an array of dosage forms. Efficacy, fewer adverse events, and convenience sound like an enticing trio of features, but Abilify may not be the best choice among the group.
Pharmafile
APRIL 4, 2025
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its immunotherapy drug Opdivo (nivolumab), marking a major step towards expanding treatment options for patients with resectable non-small cell lung cancer (NSCLC) in the EU. CHMP, part of the European Medicines Agency (EMA), has recommended […] The post Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment appeared first on Pharmafile.
Pharmacy Times
APRIL 4, 2025
Mark Mulvahill, MBA, MSc, discusses the importance of microbial preservation and reference materials in pharmaceutical manufacturing and compounding pharmacies, highlighting their role in contamination control, regulatory compliance, and enhancing microbiological testing reliability.
The Checkup by Singlecare
APRIL 4, 2025
Semaglutide (the active ingredient in brand-name drugs Ozempic , Rybelsus , and Wegovy ) is a GLP-1 receptor agonist , antidiabetic, and weight loss drug. The injectable medicine, Ozempic, is approved by the U.S. Food and Drug Administration (FDA) to treat Type 2 diabetes and lower the risk of cardiovascular events and kidney problems in certain adults.
Pharmacy Times
APRIL 4, 2025
The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.
Pharmaceutical Technology
APRIL 4, 2025
The EC has approved Daiichi Sankyo and AstraZenecas Enhertu for use as a single agent to treat adults with certain breast cancers.
Pharmacy Times
APRIL 4, 2025
BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.
pharmaphorum
APRIL 4, 2025
Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD
Pharmaceutical Technology
APRIL 4, 2025
Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.
Fierce Healthcare
APRIL 4, 2025
Experts spoke out about the impact these and future potential cuts will have on underserved patients around the U.S.
Expert insights. Personalized for you.
430 
Let's personalize your content